Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 4
2015 5
2016 1
2017 3
2018 2
2019 1
2021 2
2022 8
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
Okumura N, Tsuzuki S, Saito S, Hattori SI, Takeuchi JS, Saito T, Ujiie M, Hojo M, Iwamoto N, Sugiura W, Mitsuya H, Ohmagari N. Okumura N, et al. Among authors: takeuchi js. J Infect Chemother. 2022 Sep;28(9):1340-1343. doi: 10.1016/j.jiac.2022.04.018. Epub 2022 Apr 22. J Infect Chemother. 2022. PMID: 35644734 Free PMC article.
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato Y, Yamamoto K, Nakaya Y, Morioka S, Takeuchi JS, Takamatsu Y, Maeda K, Kimura M, Sugiura W, Mitsuya H, Yano M, Ohmagari N. Miyazato Y, et al. Among authors: takeuchi js. J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23. J Infect Chemother. 2022. PMID: 35337728 Free PMC article.
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Yamamoto S, Maeda K, Matsuda K, Tanaka A, Horii K, Okudera K, Takeuchi JS, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: takeuchi js. Clin Infect Dis. 2022 Aug 24;75(1):e683-e691. doi: 10.1093/cid/ciab1048. Clin Infect Dis. 2022. PMID: 34950947 Free PMC article.
An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
Khor SS, Omae Y, Takeuchi JS, Fukunaga A, Yamamoto S, Tanaka A, Matsuda K, Kimura M, Maeda K, Ueda G, Mizoue T, Ujiie M, Mitsuya H, Ohmagari N, Sugiura W, Tokunaga K. Khor SS, et al. Among authors: takeuchi js. Vaccines (Basel). 2022 Apr 5;10(4):563. doi: 10.3390/vaccines10040563. Vaccines (Basel). 2022. PMID: 35455312 Free PMC article.
Vif determines the requirement for CBF-β in APOBEC3 degradation.
Yoshikawa R, Takeuchi JS, Yamada E, Nakano Y, Ren F, Tanaka H, Münk C, Harris RS, Miyazawa T, Koyanagi Y, Sato K. Yoshikawa R, et al. Among authors: takeuchi js. J Gen Virol. 2015 Apr;96(Pt 4):887-892. doi: 10.1099/jgv.0.000027. Epub 2014 Dec 16. J Gen Virol. 2015. PMID: 25516542 Free PMC article.
27 results